Latest news about Aspira Pathlab
Aspira Pathlab
95.60
-1.95(-2.00%)
Company Performance:
View Company Insights1D-2.00%
1M+7.05%
6M+62.03%
1Y+54.19%
5Y+151.58%
More news about Aspira Pathlab
18May 26
Aspira Pathlab & Diagnostics Open Offer Concludes: Acquirers Accept 22,82,507 Shares at ₹55 Each
Aftertrade Broking Private Limited issued a Post-Offer Advertisement on May 18, 2026, for the concluded open offer of Aspira Pathlab & Diagnostics Limited. The offer, open from April 15 to April 28, 2026, sought to acquire 26,76,180 equity shares at ₹55/- per share; actual shares accepted stood at 22,82,507, with the actual offer size at ₹12,55,37,885/-. Post-offer, the combined stake of the Acquirers and PAC rose from 23.82% to 46.00%, while public shareholding declined from 75.75% to 53.57%.
15Apr 26
Aspira Pathlab & Diagnostics Limited Confirms Non-Applicability of Large Corporate Criteria for FY26
Aspira Pathlab & Diagnostics Limited has confirmed to BSE that it does not qualify as a Large Corporate under SEBI criteria for FY26, exempting it from annual disclosure requirements. The confirmation was submitted by CFO Balkrishna Talawadekar on April 15, 2026, referencing SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144. The company is therefore not required to comply with Annexure B2 disclosure requirements related to debt securities fund raising by Large Corporate entities.
15Apr 26
Aspira Pathlab Confirms Non-Applicability of Large Corporate Status Under SEBI Regulations
Aspira Pathlab & Diagnostics Limited confirmed to BSE Limited on April 15, 2026, that it does not qualify as a Large Corporate under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144. The company reported nil outstanding borrowings as of March 31, 2026, and confirmed that credit rating requirements are not applicable, exempting it from the regulatory framework governing large corporate debt securities issuance.
14Apr 26
Aspira Pathlab & Diagnostics Limited Files Compliance Certificate for Q4 FY26
Aspira Pathlab & Diagnostics Limited has submitted its compliance certificate under SEBI regulations for Q4 FY26, confirming proper handling of dematerialised securities. The certificate, issued by registrar MUFG Intime India Private Limited, demonstrates adherence to prescribed procedures for securities processing and maintains regulatory compliance with stock exchange requirements.
25Mar 26
Aspira Pathlab & Diagnostics Limited Sets March 27, 2026 as Record Date for Open Offer Under SEBI Takeover Regulations
Aspira Pathlab & Diagnostics Limited has set March 27, 2026 as the record date for an open offer involving 26,76,180 equity shares at ₹55 per share, representing 26% of the company's equity capital. Five acquirers led by Mr. Arvind Karsandas Bhanushali and family members, along with Mrs. Shraddha Nikunj Mange as PAC, are conducting the offer under SEBI takeover regulations. Aftertrade Broking Private Limited is managing the process, which follows a structured timeline beginning with the public announcement in September 2025.
07Mar 26
Aspira Pathlab & Diagnostics Announces Resignation of Company Secretary cum Compliance Officer
Aspira Pathlab & Diagnostics Limited announced the resignation of Company Secretary cum Compliance Officer Ms. Krupali Shah (Membership No: A70473) due to personal reasons, effective March 08, 2026. The company has made the required regulatory disclosure to BSE Limited under SEBI regulations, with Executive Director Nikunj Mange accepting the resignation on behalf of the Board of Directors.
10Feb 26
Aspira Pathlab Reports Q3FY26 Net Loss of ₹156.12 Lakhs Against Prior Year Profit
Aspira Pathlab & Diagnostics Limited reported a net loss of ₹156.12 lakhs for Q3FY26 against a profit of ₹37.66 lakhs in Q3FY25, with revenue declining 5.33% to ₹511.88 lakhs. For nine months FY26, the company maintained profitability at ₹74.03 lakhs despite a 45.17% decline from ₹135.02 lakhs in the previous year. The Board approved a ₹5 crore related party transaction with Yashraj Research Foundation subject to member approval.
07Jan 26
Aspira Pathlab Submits Quarterly Compliance Certificate for Q3FY26 Under SEBI Regulations
Aspira Pathlab & Diagnostics Limited has submitted its compliance certificate under SEBI Regulation 74(5) for Q3FY26 quarter ended December 31, 2025. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper handling of securities dematerialisation processes and adherence to prescribed timelines for regulatory compliance.
02Jan 26
Aspira Pathlab & Diagnostics Limited Announces Demise of Independent Director Dr. Alaka Keshav Deshpande
Aspira Pathlab & Diagnostics Limited announced the death of Independent Director Dr. Alaka Keshav Deshpande on December 30, 2025, at age 79. Her demise results in cessation of her directorship and memberships in the Audit Committee, Nomination & Remuneration Committee, and Stakeholder Relationship Committee. The company described her loss as irreparable and has conveyed condolences to her family while fulfilling regulatory disclosure requirements under SEBI LODR Regulations.
13Nov 25
Aspira Pathlab Reports Q2 Loss, Appoints New Independent Director
Aspira Pathlab Diagnostics Limited reported a net loss of ₹230.49 lakhs for the quarter ended September 30, compared to a profit of ₹97.36 lakhs in the same period last year. The company appointed Mrs. Kiran Raghavendra Awasthi as an Additional Independent Director for a five-year term, effective November 12. Aspira Pathlab also acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP for ₹13.00 lakhs, effective June 30.
26Sept 25
Aspira Pathlab & Diagnostics Receives Open Offer for 26% Stake at Rs. 55 Per Share
Five acquirers and a person acting in concert have announced an open offer to acquire 26.00% (26,76,180 equity shares) of Aspira Pathlab & Diagnostics Limited at Rs. 55.00 per share. The offer, announced on September 26, 2025, complies with SEBI regulations. Aspira, established in 1973, reported a profit of Rs. 2.07 crores in FY 2024-25, a turnaround from previous year's loss. The company has over 600 centers across India and added 91 new locations in the last fiscal year.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
One Global Service Provider
3B BlackBio DX
Health X Platform
1,901.40
(+1.28%)
1,497.30
(-0.62%)
551.95
(+0.22%)
608.25
(-1.67%)
699.10
(+0.64%)
540.20
(-3.27%)
318.30
(+3.19%)
537.05
(-5.00%)
1,148.40
(0.0%)
288.50
(-1.03%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
